No merit seen in including Paxlovid in Covid treatment: ICMR

Antiviral drug Molnupiravir, earlier failed to convince the ICMR for its inclusion in India's national Covid-19 treatment protocol due to "safety concerns", even as it received an emergency use authorisation (EUA) from the country's drug regulator.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uloL4U5
via IFTTT